Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen?

Current Opinion in Infectious Diseases
Marin H Kollef, Scott T Micek

Abstract

The main goal of this review is to describe the emergence of methicillin-resistant Staphylococcus aureus (MRSA) as a community pathogen. Community-acquired MRSA has emerged as an important infection in the community setting. It has primarily been associated with skin and soft-tissue infections, but can also cause severe pulmonary infections, including pneumonia and empyema. Community-acquired MRSA is typically more susceptible to a wider class of antibiotics than healthcare-associated MRSA. Community-acquired MRSA is also more virulent compared with healthcare-associated MRSA isolates. Community-acquired MRSA usually contains the gene encoding Panton-Valentive leukocidin, which is a toxin that creates lytic pores in the cell membranes of neutrophils and induces the release of neutrophil chemotactic factors that promote inflammation and tissue destruction. The optimal antibiotic treatment for Panton-Valentive leukocidin-positive community-acquired MRSA is unknown; however, antibiotics with activity against MRSA and the ability to inhibit toxin production may be optimal (linezolid or clindamycin for susceptible isolates). Clinicians should be aware of the emergence of community-acquired MRSA as an important cause of serious infec...Continue Reading

References

Sep 1, 1990·Antimicrobial Agents and Chemotherapy·G L Archer, E Pennell
Dec 1, 1994·American Journal of Respiratory and Critical Care Medicine·J RelloR Rodriguez-Roisin
Nov 1, 1996·The Journal of Antimicrobial Chemotherapy·M CrucianiE Concia
Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G LinaJ Etienne
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H RexJ E Edwards
Jun 29, 2001·The Journal of Hospital Infection·R W SmythB Hoffman
Sep 14, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Philippe DufourHervé Richet
Nov 1, 2002·Journal of Clinical Microbiology·Keiko OkumaKeiichi Hiramatsu
Dec 20, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E CosgroveYehuda Carmeli
Jan 11, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cassandra D SalgadoDavid P Calfee
Mar 26, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Teruyo ItoKeiichi Hiramatsu
Jun 6, 2003·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Carlene A MutoUNKNOWN SHEA
Nov 14, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M MelzerS Chinn
Dec 11, 2003·JAMA : the Journal of the American Medical Association·Timothy S NaimiRuth Lynfield
Jul 10, 2004·American Journal of Respiratory and Critical Care Medicine·Alain CombesUNKNOWN PNEUMA Trial Group
Dec 23, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John S FrancisJohn G Bartlett
Jan 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James S Lewis, James H Jorgensen
Apr 9, 2005·The New England Journal of Medicine·Scott K FridkinUNKNOWN Active Bacterial Core Surveillance Program of the Emerging Infections Program Network
May 18, 2005·The Journal of Infectious Diseases·Jared A SilvermanJeff Alder
Jun 1, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A Y PelegF Huygens
Jun 7, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H LindeN Lehn
Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Blanca E GonzalezSheldon L Kaplan

❮ Previous
Next ❯

Citations

Jul 9, 2008·BMC Genomics·Christina J BrandnerKamil Onder
Oct 30, 2012·The Medical Clinics of North America·Himanshu Desai, Aarti Agrawal
Jun 27, 2007·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Rei FujikiHisamichi Aizawa
Apr 21, 2007·Urology·Thomas J Beckman, Randall S Edson
Apr 3, 2007·Emergency Medicine Clinics of North America·Bradley N Younggren, Mark Denny
Nov 23, 2006·The Surgical Clinics of North America·Kristen C Sihler, Avery B Nathens
May 3, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J Chastre
Sep 7, 2006·Journal of Biochemistry·Atsuo AmanoTamotsu Yoshimori
Jul 31, 2007·Bioorganic & Medicinal Chemistry Letters·Sharaf Nawaz KhanHong-Seok Kim
Sep 19, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marin H Kollef
Feb 7, 2008·Expert Review of Anti-infective Therapy·Eszter NagyAlexander von Gabain
Apr 1, 2008·Bioorganic & Medicinal Chemistry Letters·Sharaf Nawaz KhanHong-Seok Kim
Jul 1, 2008·Enfermedades infecciosas y microbiología clínica·Marta BarriosFernando Chaves
Oct 30, 2009·Journal of Community Health Nursing·J Chad Sanders
Jan 16, 2010·Current Opinion in Infectious Diseases·Carlos M Luna, Iris D Boyeras Navarro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.